
|Articles|November 12, 2020
Pipeline: New therapies to come for debilitating eye diseases
New drug from Gensight Biologics hits pipeline
Advertisement
GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.
Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
The mechanics of presbyopia: From muscle movement to functional vision
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Crafting your own eyewear brand: Success starts with personalization
4
Majority of US patients with dry eye experience symptoms weekly, survey finds
5















































.png)


